Abstract
ABSTRACT Statins and bempedoic acid (BA) additively and independently
lower CRP. Recent secondary analyses of the CLEAR trials found CRP
lowering more effective than LDL lowering at reducing MACE (major
adverse cardiovascular events) thereby suggesting an advantage from
targeting CRP over LDL. Statins lower CRP by via targeting eNOS, whereas
BA lowers CRP via targeting ATP citrate lyase. The rationale for
combining atorvastatin 80 with BA 180 is to simultaneously target two
independent mechanisms for lowering CRP in patients with high risk of
MACE from vascular inflammation.